Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04356729 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
A Phase 2 study of Clinical Stage III Cutaneous Melanoma AJCC v8 and Stage IV Melanoma, sponsored by Elizabeth Buchbinder, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT04356729 is a Phase 2 study of Clinical Stage III Cutaneous Melanoma AJCC v8 and Stage IV Melanoma that is active but no longer recruiting, run by Elizabeth Buchbinder, MD. The registered enrollment target is 30 participants, below the 242-participant average among 23 other Clinical Stage III Cutaneous Melanoma AJCC v8 trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT04356729, a Phase 2 study of Clinical Stage III Cutaneous Melanoma AJCC v8 and Stage IV Melanoma, is active but no longer recruiting, sponsored by Elizabeth Buchbinder, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is studying a combination of two drugs that change the immune system and tumor as a possible treatment for metastatic or unresectable stage III or IV cutaneous melanoma. The names of the study drugs involved in this study are: * Atezolizumab * Bevacizumab
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
Study Locations (3)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-08-06 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04356729
The ClinicalTrials.gov registry entry for NCT04356729 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 23 other Clinical Stage III Cutaneous Melanoma AJCC v8 trials with a reported enrollment target (88% lower). The listed sponsor is Elizabeth Buchbinder, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Clinical Stage III Cutaneous Melanoma AJCC v8 appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT04356729 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04356729 about?
NCT04356729 is a clinical study titled "A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma". This research study is studying a combination of two drugs that change the immune system and tumor as a possible treatment for metastatic or unresectable stage III or IV cutaneous melanoma. The names of the study drugs involved in this study are: * Atezolizumab * Bevacizumab
What is the current status of trial NCT04356729?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-08-06. Estimated completion is 2026-09-01.
What conditions does trial NCT04356729 study?
This clinical trial studies the following conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma, Unresectable Stage IV Cutaneous Melanoma.
What interventions are being tested in trial NCT04356729?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT04356729?
This trial is sponsored by Elizabeth Buchbinder, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04356729 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clinical Stage III Cutaneous Melanoma AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RECRUITING · Phase 2
-
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
ACTIVE NOT RECRUITING · Phase 2
-
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Clinical Stage III Cutaneous Melanoma AJCC v8
All registered trials for this condition
Stage IV Melanoma
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.